New blood thinner may shorten hospital stay after heart surgery
NCT ID NCT03702582
First seen May 19, 2026 · Last updated May 19, 2026
Summary
This study tested whether a newer blood thinner (rivaroxaban) is safer and more cost-effective than the standard drug warfarin for patients who develop atrial fibrillation after heart surgery. About 100 adults who had open-heart surgery and then experienced a new irregular heartbeat were randomly assigned to receive either rivaroxaban or warfarin. The main goal was to see if the newer drug could reduce the length of hospital stay and lower the risk of major bleeding.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STROKE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.